Kantak K M, Collins S L, Lipman E G, Bond J, Giovanoni K, Fox B S
Department of Psychology, Boston University, Massachusetts 02215, USA.
Psychopharmacology (Berl). 2000 Feb;148(3):251-62. doi: 10.1007/s002130050049.
Previous pre-clinical studies with an anti-cocaine monoclonal antibody left open several issues critical to assessing the effectiveness of a vaccine for altering cocaine self-administration behavior.
The objectives of this study were to determine, first, whether changes in self-administration behavior would be systematically related to antibody level and, second, how the antibody affected the self-administration of different doses of cocaine.
Two experiments were conducted using a second-order schedule of drug delivery in rats. The first was a passive-administration study using the anti-cocaine monoclonal antibody MO240 to examine the relationship between antibody level and cocaine self-administration behavior, and the second was an active-immunization study to examine the efficacy of the cocaine vaccine IPC-1010 for blocking various doses of self-administered cocaine.
The passive-administration experiment with control and 4-mg or 12-mg MO240 treatments showed that antagonism of the 1 mg/kg cocaine training dose was dependent on antibody level. In animals whose serum antibody levels were sustained above 0.05 mg/ml, there was a sufficient amount of antibody to reduce drug-seeking behavior and drug intake. In the active-immunization experiment, the cocaine vaccine IPC-1010 induced average serum antibody levels of 0.08 mg/ml and reduced the reacquisition of behavior by 1 mg/kg cocaine. Antagonism of cocaine self-administration after immunization was evident across a range of doses of cocaine and was only apparent in animals whose serum antibody levels exceeded 0.05 mg/ml. Furthermore, there was no evidence that the antagonism was surmountable within the dose range examined (up to 5.6 mg/kg).
Antagonism of cocaine self-administration across a range of doses is feasible after immunization with a cocaine vaccine as long as antibody levels are of a sufficient concentration.
先前针对抗可卡因单克隆抗体的临床前研究留下了几个对于评估改变可卡因自我给药行为的疫苗有效性至关重要的问题。
本研究的目的首先是确定自我给药行为的变化是否会与抗体水平系统相关,其次是该抗体如何影响不同剂量可卡因的自我给药。
使用大鼠二级给药方案进行了两项实验。第一项是使用抗可卡因单克隆抗体MO240的被动给药研究,以检查抗体水平与可卡因自我给药行为之间的关系,第二项是主动免疫研究,以检查可卡因疫苗IPC - 1010阻断各种剂量自我给药可卡因的功效。
对照以及4毫克或12毫克MO240处理的被动给药实验表明,对1毫克/千克可卡因训练剂量的拮抗作用取决于抗体水平。在血清抗体水平持续高于0.05毫克/毫升的动物中,有足够量的抗体来减少觅药行为和药物摄入量。在主动免疫实验中,可卡因疫苗IPC - 1010诱导的平均血清抗体水平为0.08毫克/毫升,并减少了1毫克/千克可卡因行为的重新习得。免疫后对可卡因自我给药的拮抗作用在一系列可卡因剂量范围内均很明显,并且仅在血清抗体水平超过0.05毫克/毫升的动物中才明显。此外,没有证据表明在所检查的剂量范围内(高达5.6毫克/千克)这种拮抗作用是可克服的。
只要抗体水平达到足够浓度,用可卡因疫苗免疫后在一系列剂量范围内拮抗可卡因自我给药是可行的。